AbbVie Terminates Tau and ASN Agreement with Voyager Signed in 2018 and 2019

 AbbVie Terminates Tau and ASN Agreement with Voyager Signed in 2018 and 2019

Shots:

  • Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner
  • As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized Abs directed against tau and alpha-synuclein in AD & PD respectively
  • Voyager is not obligated to repay the upfront payment it received from AbbVie in connection with the Tau & ASN agreement but is no longer eligible to receive option payments, milestone payments, or royalties thereunder

Click here, Click here ­to­ read full press release/ article | Ref: Voyager | Image: PharmaShots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post